Viridian Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 0.256 million compared to USD 1.09 million a year ago. Net loss was USD 29.49 million compared to USD 17.96 million a year ago. Basic loss per share from continuing operations was USD 1.06 compared to USD 2.21 a year ago.
For the six months, revenue was USD 0.472 million compared to USD 2.54 million a year ago. Net loss was USD 55.18 million compared to USD 36.42 million a year ago. Basic loss per share from continuing operations was USD 2.05 compared to USD 5.04 a year ago.